.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,017,148

« Back to Dashboard

Details for Patent: 8,017,148

Title:Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant agent
Abstract: Disclosed in certain embodiments is an oral dosage form comprising: a therapeutically effective amount of an opioid analgesic; an opioid antagonist; and an irritant in an effective amount to impart an irritating sensation to an abuser upon administration of the dosage form after tampering.
Inventor(s): Sackler; Richard (Greenwich, CT)
Assignee: Purdue Pharma L.P. (Stamford, CT)
Filing Date:Sep 22, 2006
Application Number:11/525,268
Claims:1. A method of treating pain comprising administering to a patient an oral dosage form comprising: a therapeutically effective amount of an opioid analgesic; an opioid antagonist; and an irritant in an effective amount to impart an irritating sensation to an abuser upon administration of said dosage form after tampering.

2. The method of claim 1, wherein the irritant is selected from the group consisting of capsaicin, a capsaicin analog, and mixtures thereof.

3. The method of claim 1, wherein the irritant is a capsaicin analog selected from the group consisting of resiniferatoxin, tinyatoxin, heptanoylisobutylamide, heptanoyl guaiacylamide, isobutylamide, guaiacylamide, dihydrocapsaicin, homovanillyl octylester, nonanoyl vanillylamide, and mixtures thereof.

4. The method of claim 1, wherein the irritant is capsaicin.

5. The method of claim 1, wherein the irritant is vanillylamide.

6. The method of claim 1, wherein the irritant is in a sequestered form.

7. The method of claim 1, wherein the antagonist is in a sequestered form.

8. The method of claim 1, wherein the antagonist and the irritant are both in sequestered forms.

9. The method of claim 1, wherein the irritant is in an amount of about 0.00125% to about 50% by weight of the oral dosage form.

10. The method of claim 1, wherein the irritant is in an amount of about 1 to about 7.5% by weight of the oral dosage form.

11. The method of claim 1, wherein the irritant is in an amount of about 1 to about 5% by weight of the oral dosage form.

12. The method of claim 1, wherein said oral dosage form comprises a pharmaceutically acceptable excipient.

13. The method of claim 12, wherein said excipient is a sustained release excipient.

14. The method of claim 1, wherein said oral dosage form provides an analgesic effect for at least about 12 hours after oral administration to a human patient.

15. The method of claim 1, wherein said irritant is at least partially interdispersed with the opioid analgesic.

16. The method of claim 1, comprising combining the opioid antagonist and said opioid analgesic prior to the administration in a ratio of opioid antagonist to opioid analgesic such that the combination is analgesically effective when administered orally, but is aversive in physically dependent human subjects, when administered at the same amount or at a higher amount than said therapeutically effective amount.

17. The method of claim 16, wherein said ratio of opioid antagonist to opioid analgesic maintains an analgesic effect but does not increase analgesic efficacy of the opioid analgesic, relative to the same therapeutic amount of opioid analgesic when administered to human patients without said opioid antagonist.

18. The method of claim 1, wherein the antagonist is in an amount to attenuate a side effect of said opioid analgesic selected from the group consisting of anti-analgesia, hyperalgesia, hyperexcitability, physical dependence, tolerance, and a combination of any of the foregoing.

19. The method of claim 1, wherein the amount of antagonist released during a dosing interval enhances the analgesic potency of the opioid analgesic.

20. The method of claim 1, wherein the amount of the opioid antagonist administered is about 100 to about 1000 fold less than the amount of the opioid analgesic administered.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc